Please assess the completion status of the following clinical trial:

Trial Title: Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years at the time of signing the informed consent document.~* Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted.~* Histologically confirmed marginal zone lymphoma or follicular lymphoma (grade 1, 2 or 3a; CD20+ by flow cytometry or histochemistry).~* Previously treated with at least one prior systemic chemotherapy, immunotherapy or chemoimmunotherapy and have received at least 2 previous doses of rituximab.~* Documented relapsed, refractory or progressive disease after treatment with systemic therapy and must not be rituximab-refractory.~* Investigator considers rituximab monotherapy appropriate.~* Bi-dimensionally measurable disease on cross sectional imaging by X-ray computed tomography (CT) or magnetic resonance imaging (MRI).~* Need of treatment for relapsed, progressed or refractory disease as assessed by the investigator.~* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.~* Adequate bone marrow function.~* Willingness to follow study visit schedule, pregnancy precautions and other protocol requirements.~Exclusion Criteria:~* Histology other than follicular or marginal zone lymphoma or clinical evidence of transformation or Grade 3b follicular lymphoma.~* Subjects taking corticosteroids during the last week prior to study treatment, unless administered at a dose equivalent to \< 20 mg/day prednisone or prednisolone.~* Systemic anti-lymphoma therapy within 28 days or use of antibody agents within 8 weeks use of radioimmunotherapy within 6 months.~* Known seropositive for or active viral infection with hepatitis B virus (HBV) or/and human immunodeficiency virus (HIV).~* Known hepatitis C virus (HCV) positive with chronic HCV or active viral infection with HCV hepatitis requiring anti-viral medication (at time of randomization).~* Life expectancy \< 6 months.~* Known sensitivity or allergy to murine products.~* Prior history of malignancies, other than follicular or marginal zone lymphoma, unless the subject has been free of the disease for ≥ 5 years.~* Prior use of lenalidomide.~* Known allergy to thalidomide.~* Neuropathy \> Grade 1.~* Presence or history of central nervous system involvement by lymphoma.~* Subjects who are at a risk for a thromboembolic event and are not willing to take prophylaxis for it.~* Uncontrolled intercurrent illness.~* Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent document.~* Pregnant or lactating females.~* Any condition that places the subject at unacceptable risk if he/she were to participate in the study or that confounds the ability to interpret data from the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rituximab and Lenalidomide (Type: EXPERIMENTAL): Participants received rituximab 375 mg/m\^2 intravenously (IV) every week in Cycle 1 (Days 1, 8, 15 and 22) and on Day 1 of every 28-day cycle from Cycles 2 to 5 plus lenalidomide 20 mg by mouth (PO) once daily on Days 1 to 21 every 28 days, up to 12 cycles (21-day treatment and 7-day rest period); if creatinine clearance (CrCl) was ≥ 30 mL/min but \< 60 mL/min, participants received lenalidomide 10 mg capsules on days 1 to 21 every 28 days.
- Rituximab and Placebo (Type: ACTIVE_COMPARATOR): Participants received riituximab 375 mg/m\^2 IV every week in Cycle 1 (Days 1, 8, 15 and 22) and on Day 1 of every 28-day cycle from cycle 2 to 5 plus placebo (identically matched capsule) once daily on Days 1 to 21 of every 28-day cycle up, to 12 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).